Chronic Lower Back Pain (CLBP) - Epidemiology Forecast

List of Tables

Epidemiology Insights and Trends

According to DelveInsight's estimates, the total prevalent cases of CLBP in the 7MM were approximately 148 million in 2025.
CLBP prevalence rose from under 5% in the early 1990s to over 10% by the mid-2000s in tracking studies, and 2022 survey data put CLBP at roughly 28% of US adults, which accounts for a disproportionately high clinical and socioeconomic burden due to persistent pain, recurrent flare-ups, substantial physical disability, and long-term activity limitation.
Moderate CLBP represents the largest diagnosed subgroup, followed by mild CLBP, while severe CLBP, despite being the smallest segment, accounts for substantially higher healthcare utilization and intensive treatment.
Most CLBP cases are associated with musculoskeletal pain, primarily due to non-specific mechanical causes and degenerative spinal disorders. A smaller but clinically significant subgroup has a neuropathic pain component, often related to lumbosacral radiculopathy, spinal stenosis, or disc herniation. Although less prevalent, neuropathic CLBP is associated with greater pain severity, functional impairment, and healthcare utilization.
Despite the high disease burden, CLBP remains underdiagnosed and inconsistently characterized across epidemiological studies because of variations in diagnostic definitions, chronicity thresholds, and coding practices. Improved disease awareness, wider access to imaging and specialist care, and greater recognition of chronic pain as a distinct clinical condition are expected to increase diagnosis rates across the 7MM.
Diagnostic challenges remain significant, as delayed or misdiagnosis can lead to inappropriate interventions, including unnecessary spine surgery. Persistent pain may also affect the reliability of self-reported histories, while no single physical examination test provides sufficient accuracy. Therefore, accurate assessment requires integrating patient history, functional behavior, and multiple physical examination findings.
In recent years there has been growing interest in Modic changes, defined as bone marrow lesions adjacent to the vertebral endplate seen on MRI. There are different types of Modic changes, with different histopathological correlates. However, the natural history of these lesions, which this study aims to examine, is not well established.

Chronic Lower Back Pain (CLBP) Epidemiology Forecast in the 7MM

2025 Prevalent Cases of Chronic Lower Back Pain (CLBP): ~148 million
2036 Projected Prevalent Cases of Chronic Lower Back Pain (CLBP): XXX
Chronic Lower Back Pain (CLBP) Growth Rate (2026-2036): ~0.8% CAGR

DelveInsight's 'Chronic Lower Back Pain (CLBP) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the CLBP, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Chronic Lower Back Pain (CLBP) Understanding and Diagnosis Algorithm

Chronic Lower Back Pain (CLBP) Overview and Diagnosis

CLBP is defined as pain localized to the lower back that persists for 12 weeks or longer, often continuing beyond the expected period of tissue healing. It is one of the leading causes of disability worldwide and is associated with significant physical, psychological, and socioeconomic burden, particularly among older adults. CLBP may arise from degenerative spinal disorders, mechanical abnormalities, nerve compression, or other underlying conditions, although a specific cause is often difficult to identify.

Diagnosis is primarily based on a detailed medical history and physical examination to differentiate mechanical from non-mechanical causes, with imaging modalities such as X-ray, magnetic resonance imaging (MRI), or computed tomography (CT) reserved for patients with persistent symptoms, neurological deficits, or suspected serious underlying pathology.

Chronic Lower Back Pain (CLBP) Epidemiology

Key Findings from Chronic Lower Back Pain (CLBP) Epidemiological Analysis and Forecast

The prevalent cases of CLBP in the 7MM were 148 million in 2025, rising at a CAGR of 0.8% during the study period; this is expected to rise by 2036. This growth is primarily driven by population aging, increasing burden of degenerative spinal disorders, sedentary lifestyles, and rising obesity rates, along with improved disease recognition, greater healthcare utilization, and enhanced diagnosis of chronic pain.
Among the 7MM, the US accounted for ~50% (~76 million) of total prevalent CLBP cases in 2025; these cases are expected to increase throughout the forecast period.
DDD is the leading cause of CLBP, driven by age-related spinal degeneration and cumulative mechanical stress.
In the US, CLBP severity was predominantly moderate (~50%), followed by mild (~30%) and severe (~20%), indicating that most patients experience a clinically meaningful symptom burden.
Moderate-to-severe CLBP had a higher treatment rate in the United States, with ~32 million treated cases in 2025, compared with ~6 million treated cases for mild CLBP. The treated cases across both severity groups are projected to increase through 2036.
In the United States, among age-specific prevalent CLBP cases, patients aged 70 years and above accounted for 22 million cases, followed by those aged 50-59 in 2025, with both segments expected to increase by 2036.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of CLBP, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

CLBP Patient Population Forecast

Report Key Strengths

Epidemiology-based (epi-based) Bottom-up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs:

What are the disease risks, burdens, and unmet needs of CLBP? What will be the growth opportunities across the 7MM concerning the patient population with CLBP?
What is the historical and forecasted CLBP patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI0529

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Lower Back Pain (CLBP)

4. Epidemiology and Market Forecast Methodology of Chronic Lower Back Pain (CLBP)

5. Chronic Lower Back Pain (CLBP) Epidemiology Overview at a Glance

5.1. Patient Share (%) Distribution by Country in 2026 in the 7MM
5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM

6. Disease Background and Overview of Chronic Lower Back Pain (CLBP)

6.1. Introduction
6.2. Signs and Symptoms Related to CLBP
6.3. Pathophysiology
6.4. Classification of CLBP
6.5. Risk Factors Related to CLBP
6.6. Evaluation of Pain in CLBP
6.7. Diagnosis of CLBP
- 6.7.1. Differential Diagnosis

7. Epidemiology and Patient Population: 7MM Analysis

7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Country-Level Summary of Prevalent CLBP Cases in the 7MM
7.4. The United States
- 7.4.1. CLBP Prevalent Cases in the United States
- 7.4.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in the United States
- 7.4.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in the United States
- 7.4.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in the United States
- 7.4.5. CLBP Cases by Gender in the United States
- 7.4.6. CLBP Cases by Age-group in the United States
- 7.4.7. Treated Mild and Moderate-to-Severe CLBP Cases in the United States
7.5. EU4 and the UK
- 7.5.1. CLBP Prevalent Cases in EU4 and the UK
- 7.5.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in EU4 and the UK
- 7.5.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in EU4 and the UK
- 7.5.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in EU4 and the UK
- 7.5.5. CLBP Cases by Gender in EU4 and the UK
- 7.5.6. CLBP Cases by Age-group in EU4 and the UK
- 7.5.7. Treated Mild and Moderate-to-Severe CLBP Cases in EU4 and the UK
7.6. Japan
- 7.6.1. CLBP Prevalent Cases in Japan
- 7.6.2. CLBP Cases by Etiology (Specific vs. Non-Specific) in Japan
- 7.6.3. CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Japan
- 7.6.4. CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Japan
- 7.6.5. CLBP Cases by Gender in Japan
- 7.6.6. CLBP Cases by Age-group in Japan
- 7.6.7. Treated Mild and Moderate-to-Severe CLBP Cases in Japan

8. Patient Journey

9. KOL Views

9.1. Expert/KOL Interview Highlights

10. Appendix

10.1. Bibliography
10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Product Code: DIEI0529

List of Tables

Table 1: Summary of CLBP Epidemiology (2025-2036)
Table 2: Differential Diagnosis, Red Flags, and Evaluation of Chronic Low Back Pain
Table 3: American Academy of Family Physicians Key Recommendations For Practice (2024)
Table 4: Guideline Recommendation
Table 5: Country-Level Summary of Prevalent CLBP Cases in 7MM (in 000's) (2022-2036)
Table 6: CLBP Prevalent Cases in the United States (in 000's) (2022-2036)
Table 7: CLBP Cases by Etiology (Specific vs. Non-Specific) in the United States (in 000's) (2022-2036)
Table 8: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in the United States (in 000's) (2022-2036)
Table 9: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in the United States (in 000's) (2022-2036)
Table 10: CLBP Cases by Gender in the United States (in 000's) (2022-2036)
Table 11: CLBP Cases by Age-group in the United States (in 000's) (2022-2036)
Table 12: Treated Mild and Moderate-to-Severe CLBP Cases in the United States (in 000's) (2022-2036)
Table 13: CLBP Prevalent Cases in EU4 and the UK (in 000's) (2022-2036)
Table 14: CLBP Cases by Etiology (Specific vs. Non-Specific) in Germany (in 000's) (2022-2036)
Table 15: CLBP Cases by Etiology (Specific vs. Non-Specific) in France (in 000's) (2022-2036)
Table 16: CLBP Cases by Etiology (Specific vs. Non-Specific) in Italy (in 000's) (2022-2036)
Table 17: CLBP Cases by Etiology (Specific vs. Non-Specific) in Spain (in 000's) (2022-2036)
Table 18: CLBP Cases by Etiology (Specific vs. Non-Specific) in the UK (in 000's) (2022-2036)
Table 19: CLBP Cases by Etiology (Specific vs. Non-Specific) in EU4 and the UK (in 000's) (2022-2036)
Table 20: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Germany (in 000's) (2022-2036)
Table 21: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in France (in 000's) (2022-2036)
Table 22: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Italy (in 000's) (2022-2036)
Table 23: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy Spain (in 000's) (2022-2036)
Table 24: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in the UK (in 000's) (2022-2036)
Table 25: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in EU4 and the UK (in 000's) (2022-2036)
Table 26: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Germany (in 000's) (2022-2036)
Table 27: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in France (in 000's) (2022-2036)
Table 28: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Italy (in 000's) (2022-2036)
Table 29: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Spain (in 000's) (2022-2036)
Table 30: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in the UK (in 000's) (2022-2036)
Table 31: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in EU4 and the UK (in 000's) (2022-2036)
Table 32: CLBP Cases by Gender in Germany (in 000's) (2022-2036)
Table 33: CLBP Cases by Gender in France (in 000's) (2022-2036)
Table 34: CLBP Cases by Gender in Italy (in 000's) (2022-2036)
Table 35: CLBP Cases by Gender in Spain (in 000's) (2022-2036)
Table 36: CLBP Cases by Gender in the UK (in 000's) (2022-2036)
Table 37: CLBP Cases by Gender in EU4 and the UK (in 000's) (2022-2036)
Table 38: CLBP Cases by Age-group in Germany (in 000's) (2022-2036)
Table 39: CLBP Cases by Age-group in France (in 000's) (2022-2036)
Table 40: CLBP Cases by Age-group in Italy (in 000's) (2022-2036)
Table 41: CLBP Cases by Age-group in Spain (in 000's) (2022-2036)
Table 42: CLBP Cases by Age-group in the UK (in 000's) (2022-2036)
Table 43: CLBP Cases by Age-group in EU4 and the UK (in 000's) (2022-2036)
Table 44: Treated Mild and Moderate-to-Severe CLBP Cases in Germany (in 000's) (2022-2036)
Table 45: Treated Mild and Moderate-to-Severe CLBP Cases in France (in 000's) (2022-2036)
Table 46: Treated Mild and Moderate-to-Severe CLBP Cases in Italy (in 000's) (2022-2036)
Table 47: Treated Mild and Moderate-to-Severe CLBP Cases in Spain (in 000's) (2022-2036)
Table 48: Treated Mild and Moderate-to-Severe CLBP Cases in the UK (in 000's) (2022-2036)
Table 49: Treated Mild and Moderate-to-Severe CLBP Cases in EU4 and the UK (in 000's) (2022-2036)
Table 50: CLBP Prevalent Cases in Japan (in 000's) (2022-2036)
Table 51: CLBP Cases by Etiology (Specific vs. Non-Specific) in Japan (in 000's) (2022-2036)
Table 52: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Japan (in 000's) (2022-2036)
Table 53: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Japan (in 000's) (2022-2036)
Table 54: CLBP Cases by Gender in Japan (in 000's) (2022-2036)
Table 55: CLBP Cases by Age-group in Japan (in 000's) (2022-2036)
Table 56: Treated Mild and Moderate-to-Severe CLBP Cases in Japan (in 000's) (2022-2036)

List of Figures

Figure 1: Classification of Chronic Lower Back Pain (CLBP)
Figure 2: Country-Level Summary of Prevalent CLBP Cases in 7MM (2022-2036)
Figure 3: CLBP Prevalent Cases in the United States (2022-2036)
Figure 4: CLBP Cases by Etiology (Specific vs. Non-Specific) in the United States (2022-2036)
Figure 5: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in the United States (2022-2036)
Figure 6: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in the United States (2022-2036)
Figure 7: CLBP Cases by Gender in the United States (2022-2036)
Figure 8: CLBP Cases by Age-group in the United States (2022-2036)
Figure 9: Treated Mild and Moderate-to-Severe CLBP Cases in the United States (2022-2036)
Figure 10: CLBP Prevalent Cases in EU4 and the UK (2022-2036)
Figure 11: CLBP Cases by Etiology (Specific vs. Non-Specific) in EU4 and the UK (2022-2036)
Figure 12: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in EU4 and the UK (2022-2036)
Figure 13: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in EU4 and the UK (2022-2036)
Figure 14: CLBP Cases by Gender in EU4 and the UK (2022-2036)
Figure 15: CLBP Cases by Age-group in EU4 and the UK (2022-2036)
Figure 16: Treated Mild and Moderate-to-Severe CLBP Cases in EU4 and the UK (2022-2036)
Figure 17: CLBP Prevalent Cases in Japan (2022-2036)
Figure 18: CLBP Cases by Etiology (Specific vs. Non-Specific) in Japan (2022-2036)
Figure 19: CLBP Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy in Japan (2022-2036)
Figure 20: CLBP Cases by Disease Severity (Mild, Moderate, and Severe) in Japan (2022-2036)
Figure 21: CLBP Cases by Gender in Japan (2022-2036)
Figure 22: CLBP Cases by Age-group in Japan (2022-2036)
Figure 23: Treated Mild and Moderate-to-Severe CLBP Cases in Japan (2022-2036)

Chronic Lower Back Pain (CLBP) - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Epidemiology Insights and Trends

Chronic Lower Back Pain (CLBP) Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Lower Back Pain (CLBP)

4. Epidemiology and Market Forecast Methodology of Chronic Lower Back Pain (CLBP)

5. Chronic Lower Back Pain (CLBP) Epidemiology Overview at a Glance

6. Disease Background and Overview of Chronic Lower Back Pain (CLBP)

7. Epidemiology and Patient Population: 7MM Analysis

8. Patient Journey

9. KOL Views

10. Appendix

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

List of Figures